National Association of Testing Authorities, Australia
Scope of Accreditation
Clinipath Pathology
Site
Osborne Park Laboratory
Accreditation No.
2619
Site No.
2612
Date of Accreditation
05 May 1989
Contact
Availability
Services available to external clients
Supervision
GX (General)
Scope of Accreditation
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Anatomical pathology - Cytopathology - Cervical cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Cervical smear; Cervical tissue | Cytological examination; Immediate imprint cytology diagnosis; Review and reporting of cervical cytological material |
Liquid based cytology specimens from cervix | Cytological examination; Review and reporting of cervical cytological material | |
Anatomical pathology - Cytopathology - Gynaecological (non-cervical) cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Vaginal smears; Vaginal tissue; Vault smears; Vulval smears | Cytological examination; Immediate imprint cytology diagnosis; Review and reporting of gynaecological (non-cervical tissue) cytological samples |
Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of body fluids, exudates, washings and brushings from non-squamous mucosal sites for the detection of malignancy | Bronchial lavage; Cerebrospinal fluid (CSF); Other body fluids; Pericardial fluid; Sputum; Synovial fluid; Washings or brushings from other sites | Cytological examination; Review and reporting of cytology samples |
Urine | Cytological examination; Review and reporting of cytology samples | |
Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of nipple discharge or smears from squamous mucosal sites for the detection of cancerous or precancerous changes | Nipple discharge; Skin smears | Cytological examination; Review and reporting of cytology samples |
Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations on samples obtained via fine needle aspiration biopsy | Fine needle aspirates (FNA) | Cytological examination; Review and reporting of fine needle aspiration samples |
Anatomical pathology - Cytopathology - Testing for the National Cervical Screening Program | Liquid based cytology specimens from cervix; Liquid based cytology specimens from vaginal vault | Human papilloma virus (HPV); Cytological examination; Review and reporting of cervical cytological material |
Self-collected vaginal swabs | Human papilloma virus (HPV) | |
Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin fixed tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities; Structured reporting |
Formalin fixed tissue; Fresh tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities; Structured reporting | |
Anatomical pathology - Tissue pathology - Gene probes using paraffin in-situ hybridisation techniques (chromogenic/silver) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue | Intra-operative consultation and examination of biopsy material |
Anatomical pathology - Tissue pathology - Immunohistochemical (immunofluorescence) investigation | Fresh tissue; Frozen tissue | Detection of antigenic targets - Various |
Anatomical pathology - Tissue pathology - Immunohistochemical investigation | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of antigenic targets - Various |
Detection of antigenic targets - Various | ||
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Formalin-fixed paraffin-embedded (FFPE) tissues | BRAF mutation analysis; KRAS mutation analysis; NRAS-BRAF mutation analysis |
ISO 15189 (2012)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Anti-thyroid receptor antibodies |
Immunopathology - Quantitative and/or qualitative investigation of proteins | Serum | Cryofibrinogen; Cryoglobulins |
ISO 15189 (2022)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Serum | Carbamazepine; Digoxin; Lithium; Phenytoin (dilantin); Valproate (valproic acid, epilim) |
Chemical pathology - Detection and/or quantitation of tumour markers | Plasma; Serum | β2-Microglobulin (B2M) |
Serum | CA19-9 antigen (CA19-9); Human chorionic gonadotropin (hCG) | |
CA125 antigen (CA125); CA15-3 antigen (CA15-3); Carcinoembryonic antigen (CEA); α-Fetoprotein (AFP) | ||
Prostate specific antigen (PSA); Prostate specific antigen (PSA) fractions and derived index | ||
Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma | Aldosterone; Renin |
Plasma; Serum | Cortisol; Dehydroepiandrosterone sulfate (DHEAS); Follicle stimulating hormone (FSH); Luteinising hormone (LH); Oestradiol; Parathyroid hormone (PTH); Progesterone; Prolactin; Sex hormone binding globulin (SHBG); Testosterone - Free; Testosterone - Total | |
Insulin-like growth factor 1 (IGF-1, somatomedin C) | ||
Adrenocorticotropic hormone (ACTH); Androstenedione; Anti-Mullerian hormone (AMH); C-peptide; Growth hormone; Insulin | ||
Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
Chemical pathology - Further investigation of cardiac function | Plasma; Serum | N-Terminal-pro b-type natriuretic peptide (NT-proBNP); Troponin I |
Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Plasma; Serum | HDL - Quantitation |
Chemical pathology - Further investigation of renal and/or hepatic function | Plasma; Serum | Haptoglobins; α1-Antitrypsin |
Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Other body fluids | Amylase; Lactate dehydrogenase (LDH); Lipase; Protein - Total |
Plasma; Serum | Alanine aminotransferase; Albumin; Alkaline phosphatase; Amylase; Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Bilirubin - Total; C-reactive protein (CRP); Calcium - Total; Chloride; Cholesterol - Total; Creatine kinase; Creatinine; Glucose; High sensitivity C-reactive protein (CRP); Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea; γ-Glutamyltransferase | |
Plasma; Serum; Urine | Osmolality | |
Serum | Calcium - Ionised | |
Urine | Amylase; Calcium - Total; Chloride; Creatinine; Glucose; Magnesium; Microalbumin; Phosphate; Potassium; Protein - Total; Sodium; Urate; Urea | |
Chemical pathology - Investigation for folate deficiency | Plasma; Serum | Folate; Red blood cell folate |
Chemical pathology - Investigation of Helicobacter pylori colonisation or eradication | Breath | C13; C14 |
Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Serum | Free β-human chorionic gonadotropin (free β-hCG); Pregnancy associated plasma protein A (PAPP-A) |
Chemical pathology - Iron studies | Plasma; Serum | Ferritin; Iron; Transferrin |
Chemical pathology - Markers of bone metabolism | Urine | n-Telopeptide (NTx) |
Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Chemical pathology - Quantitation of precursor and intermediary metabolites | Plasma | Amino acids; Homocysteine |
Chemical pathology - Quantitation of vitamin B markers | Plasma; Serum | Holotranscobalamin (active vitamin B12) |
Chemical pathology - Quantitation of vitamins | Plasma; Serum | Cobalamin (vitamin B12) |
25-Hydroxyvitamin D | ||
Chemical pathology - Tests for thyroid function | Plasma; Serum | Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free |
Chemical pathology - Trace element analysis | Blood | Arsenic; Cadmium; Lead; Mercury |
Plasma; Serum | Copper; Selenium; Zinc | |
Urine | Arsenic; Cadmium; Copper; Lead; Mercury; Selenium; Zinc | |
Infertility and pregnancy tests including assisted reproductive technology - Diagnosis of pregnancy | Plasma; Serum | Human chorionic gonadotropin (hCG) |
Urine | Human chorionic gonadotropin (hCG) | |
Infertility and pregnancy tests including assisted reproductive technology - Diagnosis or follow up of threatened abortion and/or diagnosis of ectopic pregnancy | Plasma; Serum | Human chorionic gonadotropin (hCG) - Quantitative total |
ISO 15189 (2022)
Legal
Service | Product | Determinant |
---|---|---|
Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at client sites | Urine | Cocaine metabolites |
Medico legal drug testing AS/NZS 4308:2023, Section 3 Onsite screening test procedure - Testing performed at client sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Creatinine; Opiates; Specific gravity; pH |
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Chemical pathology - Detection and/or quantitation of tumour markers - Testing for the National Bowel Cancer Screening Program | Faeces | Blood |
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
Haematology - Bone marrow examination | Bone marrow | Examination of aspirated material |
Haematology - Diagnosis of thalassemia | Blood | Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation |
Haematology - Examination of blood films by special staining | Blood | Haemoglobin H |
Malaria | ||
Haematology - Full blood examination | Blood | Morphology |
Differential number; Erythrocyte count (red blood cell count, RBCC); Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Platelet count; Red blood cell index or indices; Reticulocytes | ||
Morphology | ||
Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | Platelet function (PFA) |
Plasma | Activated partial thromboplastin time (APTT); Anti-thrombin III; D-dimer; Factor IX; Factor VIII; Factor XI; Factor XII; Factor XIII; Fibrinogen; International normalised ratio (INR); Lupus anticoagulant; Protein C and protein S; Prothrombin time (PT); Thrombin time (TT); Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | |
Haematology - Investigation of haemoglobinopathy (excluding thalassemia) | Blood | Haemoglobin fraction (S, C, D, E) - Quantitation |
Haemoglobin S (HbS) - Presence | ||
Other abnormal haemoglobins | ||
Haematology - Investigation of haemolysis | Serum | Cold agglutinins |
Haematology - Limited blood examination | Blood | Erythrocyte (RBC) sedimentation rate (ESR) |
Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Blood | Plasmodium falciparum; Plasmodium knowlesi; Plasmodium malariae; Plasmodium ovale curtisi; Plasmodium ovale wallikeri; Plasmodium vivax |
Microbiology - Parasitology - Detection of ova, cysts and parasites | Blood | Malaria |
Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood | Infectious mononucleosis |
Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Blood | e1a2 BCR/ABL1 transcript |
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Immunohaematology - Blood group antibody detection | Blood | Other blood group systems; Rh phenotypes |
Immunohaematology - Blood grouping | Blood | ABO; RhD |
Immunohaematology - Determination of compatibility of blood donor units | Blood | Identification of detected antibodies |
Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor | ||
Immunohaematology - Identification and quantitation of blood group antibodies | Blood | Antibody titration |
Other blood group antibodies; Red blood cell phenotyping; Rh | ||
Immunohaematology - Investigation of blood transfusion reactions | Blood products | Antibodies; Contamination - Microbiological; Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
Immunohaematology - Issue and release of blood and blood product for transfusion | Blood | Issue and release of blood and blood products for transfusion |
Immunohaematology - Storage and distribution of blood and blood components | Blood; Blood products | Issue and release of blood and blood products for transfusion |
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Blood | CD10; CD16; CD19; CD20; CD23; CD3; CD4; CD45; CD5; CD56; CD8; HLA-B27; HLA-DR antigen; Kappa light chains; Lambda light chains |
Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Anti-cyclic citrullinated peptide antibodies (CCP); Rheumatoid factor |
Anti-Saccharomyces cerevisiae antibodies (ASCA); Anti-cardiolipin antibodies (ACA); Anti-deamidated gliadin antibodies; Anti-dense fine speckle 70 antibodies; Anti-double stranded DNA antibodies (dsDNA); Anti-extractable nuclear antigen antibodies (ENA); Anti-glomerular basement membrane antibodies (anti-GBM); Anti-intrinsic factor antibodies (IF); Anti-liver-kidney microsomes type 1 (LKM1) antibodies; Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-myeloperoxidase antibodies (MPO); Anti-parietal cell antibodies; Anti-proteinase 3 antibodies (PR3); Anti-tissue transglutaminase antibodies (tTG); Anti-β2-glycoprotein-I antibodies | ||
Anti-Ku antibodies; Anti-NOR 90 antibodies; Anti-Pm/Scl-100 antibodies; Anti-Pm/Scl-75 antibodies; Anti-RNA polymerase III - RP11, RP155; Anti-Ro-52 antibodies; Anti-Scl-70 antibodies; Anti-centromere protein A antibodies (Cenp-A); Anti-centromere protein B antibodies (Cenp-B); Anti-extractable nuclear antigen antibodies (ENA); Anti-fibrillarin antibodies; Anti-liver antibodies; Anti-myositis antibodies; Anti-nuclear antibodies (ANA); Anti-platelet derived growth factor (PDGF) receptor-α antibodies; Anti-platelet derived growth factor (PDGF) receptor-β antibodies; Anti-tyrosine hydroxylase antibodies (Th/To) | ||
Anti-thyroglobulin antibodies (Tg); Anti-thyroid peroxidase antibodies (TPO) | ||
Anti-neutrophil cytoplasmic antibodies (ANCA); Anti-nuclear antibodies (ANA); Anti-tissue antigen antibodies | ||
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential component testing (purified native and/or recombinant allergens)) | Serum | Ara h2 - Peanut; Omega-5-gliadin - Wheat; α-Lactalbumin - Milk |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential drug allergens) | Serum | Amoxicilloyl group; Ampicilloyl group; Cefaclor; Penicilloyl G; Penicilloyl V |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential epidermal and animal protein allergens) | Serum | Animal mix; Caged bird mix; Cat epithelium; Chicken feathers; Cow dander; Dog dander; Dog epithelium; Feather mix; Goat epithelium; Guinea pig epithelium; Horse dander; Mouse epithelium; Rabbit epithelium; Rat epithelium; Sheep epithelium; Swine epithelium |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [additives] allergens) | Serum | Cochineal extract (carmine red, E120) |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [egg and fowl] allergens) | Serum | Chicken; Egg; Egg white; Egg yolk |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fish, shellfish and molluscs] allergens) | Serum | Blue mussel; Codfish; Crab; Crayfish; Lobster; Octopus; Oyster; Salmon; Scallop; Seafood mix; Shrimp; Squid; Tuna |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fruit and vegetable] allergens) | Serum | Apple; Apricot; Asparagus; Aubergine (eggplant); Avocado; Banana; Blackberry; Blueberry; Broccoli; Cabbage; Carrot; Cauliflower; Celery; Cherry; Cucumber; Date; Fig; Fruit mix; Garlic; Grape; Grapefruit; Kiwi; Lemon citrus; Lime citrus; Mango; Melon; Olive - Black, fresh; Onion; Orange citrus; Papaya; Passion fruit; Peach; Pear; Pineapple; Plum; Potato; Pumpkin; Raspberry; Spinach; Strawberry; Sweet potato; Tomato; Watermelon |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [meat] allergens) | Serum | Beef; Meat mix; Mutton; Pork |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [milk] allergens) | Serum | Casein; Cheese - Cheddar type; Cow’s whey; Goat milk; Milk |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [miscellaneous] allergens) | Serum | Baker's yeast; Cacao; Coffee; Malt; Mushroom; Staple food mix; Tea |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [seeds, legumes and nuts] allergens) | Serum | Almond; Barley; Brazil nut; Buck wheat; Cashew nut; Chick pea; Coconut; Gluten; Green bean; Hazelnut; Lentil; Linseed; Lupin seed; Macadamia nut; Maize; Nut panel; Oat; Pea; Peanut; Pecan nut; Pinenut; Pistachio; Poppy seed; Quinoa; Rapeseed; Red kidney bean; Rice; Rye; Sesame seed; Soy bean; Walnut; Wheat |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [spices] allergens) | Serum | Black pepper; Caraway; Cardamon; Chilli pepper; Clove; Ginger; Green pepper - Unripe seed; Lovage; Mace; Marjoram; Mustard; Paprika (sweet pepper); Parsley; Spice mix; Tarragon; Thyme |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential grass pollen allergens) | Serum | Bahia grass; Bermuda grass; Grass mix; Johnson grass; Perennial rye grass; Timothy grass |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential insect allergens) | Serum | Cockroach; Fire ant; Mosquito |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential microorganism allergens) | Serum | Acremonium kiliense; Alternaria alternata; Alternaria tenius; Aspergillus flavus; Aspergillus fumigatus; Candida albicans; Cladosporium herbarum; Fusarium verticillioides (Fusarium moniliforme); Penicillium chrysogenum (formerly Penicillium notatum); Penicillium glabrum; Setomelanomma rostrata (Helminthosporium halodes); Mould mix |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential mite allergens) | Serum | Dermatophagoides farinae house dust mite; Dermatophagoides pteronyssinus house dust mite |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential occupational allergens) | Serum | Cotton seed; Formaldehyde/formalin; Hexamethylene diisocyanate (1,6-hexamethylene diisocyanate; 1,6-HDI); House dust; Latex; Methylene diphenyl diisocyanate (MDI, isocyanate MDI, diphenylmethane diisocyanate); Phthalic anhydride; Sunflower seed; Toluene-2,4-diisocyanate (2,4-TDI) |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential tree pollen allergens) | Serum | Acacia; Eucalyptus; Melaleuca; Oil palm; Olive; Silver birch; White pine; Willow salix |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential venom allergens) | Serum | Bee venom; Common wasp (yellow jacket) venom; Honey bee venom; Paper wasp venom |
Immunopathology - Detection of immunoglobulin E specific antibodies (to potential weed pollen allergens) | Serum | Flower mix; Weed mix |
Immunopathology - Quantitation of complement proteins | Plasma; Serum | Complement components C3 and C4 |
Immunopathology - Quantitative and/or qualitative investigation of proteins | Faeces | Calprotectin |
Plasma; Serum | Protein classes | |
Serum | Detection and quantitation of free kappa and free lambda light chains | |
Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Serum | Immunoglobulin G (IgG) subclasses |
Total immunoglobulin A; Total immunoglobulin G; Total immunoglobulin M | ||
Total immunoglobulin E | ||
Immunopathology - Single HLA antigen typing | Blood | HLA-B27 |
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Chemical pathology - Detection of faecal occult blood | Faeces | Blood |
Infertility and pregnancy tests including assisted reproductive technology - Semen analysis (other than post vasectomy) | Semen | Volume |
Agglutination; Morphology; Motility | ||
Liquefaction | ||
Sperm number | ||
pH | ||
Infertility and pregnancy tests including assisted reproductive technology - Semen analysis for post vasectomy and/or examination of cervical mucus | Semen | Presence of spermatozoa |
Microbiology - Bacteriology - Detection of pathogenic bacteria | Aspirates; Bacterial isolates; Biopsy specimens; Blood; Cerebrospinal fluid (CSF); Cervical swabs; Ear swabs; Eye swabs; Faeces; Fluids; Gastric biopsy; General swabs; Genital swabs; Human breast milk; Infusates; Isolates; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Operative specimens; Post-operative wounds; Pus; Rectal swabs; Respiratory specimens; Serum; Skin; Sputum; Superficial sites; Synovial fluid; Throat swabs; Tissues; Urethra; Urine; Vaginal swabs; Wound swabs | Bacteria; Pathogenic identification; Pathogenic microorganisms |
Aspirates; Biopsy specimens; Blood; Cerebrospinal fluid (CSF); Cervical swabs; Cord tissue; Ear swabs; Eye swabs; Faeces; Fluids; Gastric biopsy; General swabs; Genital swabs; Glass slide; Human breast milk; Infusates; Isolates; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Operative specimens; Plasma; Post-operative wounds; Pus; Rectal swabs; Respiratory specimens; Serum; Skin; Sputum; Superficial sites; Synovial fluid; Throat swabs; Tissues; Urethra; Urine; Vaginal swabs; Wound swabs | Antibiotic susceptibility; Bacteria; Pathogenic microorganisms | |
Aspirates; Biopsy specimens; Blood; Cerebrospinal fluid (CSF); Cervical swabs; Ear swabs; Eye swabs; Faeces; Fluids; Gastric biopsy; General swabs; Genital swabs; Glass slide; Human breast milk; Infusates; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Operative specimens; Plasma; Post-operative wounds; Pus; Rectal swabs; Respiratory specimens; Skin; Sputum; Superficial sites; Synovial fluid; Throat swabs; Tissues; Urethra; Urine; Vaginal swabs; Wound swabs | Bacteria; Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
Aspirates; Biopsy specimens; Blood; Cerebrospinal fluid (CSF); Cervical swabs; Ear swabs; Eye swabs; Faeces; Fluids; Gastric biopsy; General swabs; Genital swabs; Human breast milk; Infusates; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Operative specimens; Plasma; Post-operative wounds; Pus; Rectal swabs; Respiratory specimens; Skin; Sputum; Superficial sites; Synovial fluid; Throat swabs; Tissues; Urethra; Urine; Vaginal swabs; Wound swabs | Bacteria; Pathogenic microorganisms | |
Blood | Bacteria; Pathogenic microorganisms | |
Urine | Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
Microbiology - Environmental investigations and/or infection control | Spore strips | Bacterial growth - Sterility |
Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Blood; General swabs; Hair; Nails; Skin scrapings | Fungi identification; Yeasts identification |
Fungi identification; Yeasts identification | ||
Fungi identification; Yeasts identification | ||
Microbiology - Parasitology - Detection of ova, cysts and parasites | Faeces | Cysts; Ova; Parasites |
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Combined nose and throat swabs | Bordetella parapertussis; Bordetella pertussis; Mycoplasma pneumoniae |
Dry swabs; Urine | Chlamydia trachomatis; Neisseria gonorrhoeae | |
Neisseria gonorrhoeae | ||
Faeces | Aeromonas spp.; Campylobacter spp.; Escherichia coli - Enteroinvasive (EIEC); Salmonella spp.; Shigella spp.; Vibrio spp.; Yersinia enterocolitica | |
Clostridioides difficile | ||
Genital swabs | Treponema pallidum | |
Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Faeces | Blastocystis hominis; Cryptosporidium spp.; Cyclospora cayetanensis; Dientamoeba fragilis; Entamoeba histolytica; Giardia intestinalis |
Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Buccal swabs; Eye swabs; Mouth swabs; Nasal swabs; Rash swabs; Rectal swabs; Skin swabs | Herpes simplex virus (HSV); Varicella zoster virus (VZV) |
Combined nose and throat swabs; Nasopharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
Dry swabs | Adenovirus; Human metapneumovirus; Influenza A virus; Influenza B virus; Parainfluenza virus type 1/2/3/4; Respiratory syncytial virus (RSV); Rhinovirus | |
Faeces | Adenovirus F40; Adenovirus F41; Astrovirus; Norovirus G1; Norovirus G2; Rotavirus; Sapovirus | |
Genital swabs | Herpes simplex virus (HSV); Varicella zoster virus (VZV) | |
Liquid based cytology specimens | Human papilloma virus (HPV) | |
Nasal swabs; Nasopharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
Microbiology - Molecular biology - Surveillance programme for the detection of microbial nucleic acids (viruses) in accordance with Commonwealth and/or State Health protocols | Saliva | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) |
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Chemical pathology - Investigation of Helicobacter pylori colonisation or eradication | Breath | C13; C14 |
Microbiology - Mycobacteriology - Tests for antigen lymphocyte stimulation | Plasma | Mycobacterium tuberculosis cell mediated immune response |
Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Plasma; Serum | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) antibody |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) antibody | ||
Serum | Hepatitis C virus (HCV) | |
Syphilis Treponema pallidum antibody | ||
Cytomegalovirus antibody (anti-CMV) IgM; Epstein-Barr virus IgG antibody; Epstein-Barr virus IgM antibody; Epstein-Barr virus nuclear antigen; Helicobacter pylori IgG antibody; Hepatitis C virus (HCV); Herpes simplex virus type 2 antibody (anti-HSV2) - IgG; Herpes simplex type 1 antibody (anti-HSV1) - IgG; Measles IgG antibody; Measles IgM antibody; Mumps virus IgG antibody; Mumps virus IgM antibody; Parvovirus IgG antibody; Parvovirus IgM antibody; Varicella zoster virus (VZV) IgG antibody; Varicella zoster virus IgM antibody | ||
Cytomegalovirus antibody (anti-CMV) IgG; Cytomegalovirus antibody (anti-CMV) IgM; Hepatitis A virus antibody (anti-HAV) - IgG; Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus core antibody (anti-HBc) - Total; Hepatitis B virus envelope antigen (HBe Ag); Hepatitis B virus surface antibody (anti-HBs); Hepatitis C virus (HCV); Human immunodeficiency virus (HIV); Human immunodeficiency virus (HIV) subtype O; Rubella IgG antibody; Rubella IgM antibody; Syphilis Treponema pallidum antibody; Toxoplasma spp. IgG antibody; Toxoplasma spp. IgM antibody | ||
Barmah forest virus IgG antibody; Barmah forest virus IgM antibody; Ross River virus IgG antibody; Ross River virus IgM antibody |
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Urine | 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP); Buprenorphine; Dihydrocodeine (6α-hydrocodol); Fentanyl; Hydrocodone; Hydromorphone; Methadone; Norbuprenorphine; Norfentanyl; O-Desmethyltramadol; Oxycodone; Oxymorphone; Pholcodine; Tramadol |
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP); Methadone | ||
6-Acetylmorphine; Barbiturates; Buprenorphine; Methadone metabolites; Oxycodone; Phencyclidine; Propoxyphene | ||
Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Plasma; Serum | Clozapine |
ISO 15189 (2022)
Legal
Medicare expiry date
05 Jan 2026
Last Activity Date
23 Nov 2023
Service | Product | Determinant |
---|---|---|
Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Specific gravity; pH |
Medico legal drug testing AS/NZS 4308:2008, section 2 Specimen collection, storage, handling and dispatch | Urine | Colour; Creatinine; Temperature; pH |
Medico legal drug testing AS/NZS 4308:2008, section 3 General laboratory requirements | Urine | General laboratory requirements as described in AS/NZS 4308 |
Medico legal drug testing AS/NZS 4308:2008, section 4 Laboratory screening procedures | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Oxidants; Urea |
Medico legal drug testing AS/NZS 4308:2008, section 5 Laboratory confirmatory procedures | Urine | 6-Acetylmorphine; 7-Amino-clonazepam; 7-Amino-flunitrazepam; 7-Amino-nitrazepam; Amphetamines; Benzoylecgonine (ecgonine benzoate); Codeine; Diazepam; Ecgonine methyl ester; Ephedrine; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Nordiazepam; Oxazepam; Phentermine; Pseudoephedrine (PSE); Temazepam; α-Hydroxyalprazolam |
11-nor-δ-9-Tetrahydrocannabinol-9-carboxylic acid; 6-Acetylmorphine; Amphetamines; Codeine; Ephedrine; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Phentermine; Pseudoephedrine (PSE) | ||
Medico legal drug testing AS/NZS 4760, section 2 Collection, storage, handling and dispatch | Oral fluid | Handling and dispatch; Sample collection and storage |
Medico legal drug testing AS/NZS 4760, section 5 Laboratory confirmatory procedures | Oral fluid | 6-Acetylmorphine; Amphetamines; Benzoylecgonine (ecgonine benzoate); Cocaine; Codeine; Ecgonine methyl ester; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Oxycodone; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
2619
Site No.
2612
Print date
08 Oct 2024